Left Atrial Volume Changes Who Underwent Cardioversion and Recurrence of AF After RF Ablation in Persistent AF (SAFE-AF)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-07-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Electrical/pharmacological cardioversion improves structural remodeling of left atrium. We hypothesize that persistent atrial fibrillation (AF) patients with more significant left atrial size reduction after cardioversion have lower AF recurrence rates following radiofrequency ablation. The aim is to evaluate the relationship between changes in left atrial size 3 to 6 months after cardioversion and the recurrence rate of atrial fibrillation following radiofrequency ablation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Outcomes of Persistent Atrial Fibrillation Ablation Using Ablation Index-guided Radiofrequency Catheter Ablation in Patients With Continuous Monitoring

NCT05406310

Persistent Atrial Fibrillation

WITHDRAWN

Cardiac Surgical Treatment by Radiofrequency Ablation on Valvular Patients: Efficacy at 3 Months

NCT00259623

Atrial Fibrillation

COMPLETED NA

Optimal Ablation Strategies for Persistent AF With HF

NCT07153718

Heart Failure Persistent Atrial Fibrillation

ACTIVE_NOT_RECRUITING NA

Evaluation of Recurrence Risk of Atrial Fibrillation After Cryoballoon Ablation

NCT05492760

Atrial Fibrillation

UNKNOWN

A New Operation for the Treatment for Long-standing Atrial Fibrillation

NCT03347695

Cardiovascular Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Atrial fibrillation (AF) is estimated to affect over 33 million people worldwide and is associated with significant co-morbidities such as embolic stroke, heart failure, dementia. Consequently, AF poses a significant burden to the healthcare system, in both direct and indirect costs. The management of AF is complex, especially for patients with persistent AF, which is defined as sustained AF for \> 7 days. It is preferable to terminate the AF and restore normal sinus rhythm for relief of symptoms associated with AF or improvement of cardiac structure and function. The maintenance of AF, especially persistent AF is associated with fibrosis of left atria. Furthermore, AF itself promotes fibrosis, which in turn leads to increased conduction heterogeneity within the atrial substrate resulting in further progression of AF. In animal models, alterations in myocytes after sustained AF resemble those of myocardial hibernation. Ultimately, these structural changes would lead to Calcium overload and metabolic stress, similar changes have been observed in humans. In humans, atrial dilatation and degenerative changes have been observed. Interstitial fibrosis is the prime cause of structural remodeling in left atrium. In AF patients who did not experience AF recurrence after catheter ablation, the reduction in left atrial size was more significant. In the past, a 15% reduction in left atrial volume has been defined as left atrial reverse remodeling and is associated with the maintenance of sinus rhythm after AF ablation. It remains unclear whether the reduction in left atrial size after the restoration of sinus rhythm through electrical or pharmacological cardioversion in patients with persistent AF can predict AF recurrence following radiofrequency ablation.

Objectives: To evaluate the relationship between changes in left atrial size 3-6 months after electrical or pharmacological cardioversion in patients with persistent AF and AF recurrence within one year following radiofrequency ablation.

Methods: This study will be an observational trial of patients with persistent AF. Candidates will be identified among inpatients or outpatients if they have had at least two echocardiograms, one before and one 3-6 months after pharmacological or electrical cardioversion. Heart rhythm will be assessed through medical records and telephone surveys.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Persisent Atrial Fibrillation Reversal of Atrial Enlargement Recurrence of Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Reversible Group

Left atrial volume (LAV) decreased by 15% 3 to 6 months after electrical/pharmacological cardioversion compared to baseline. Consequently, patients in the group will receive pulmonary vein isolation only.

1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation

Intervention Type DIAGNOSTIC_TEST

1\. electrical/pharmacological cardioversion. 2. pulmonary vein isolation for persistent atrial fibrillation

Irreversible Group

Left atrial volume (LAV) decreased by less than 15% 3 to 6 months after electrical/pharmacological cardioversion compared to baseline. Patients in the group will receive pulmonary vein isolation only.

1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation

Intervention Type DIAGNOSTIC_TEST

1\. electrical/pharmacological cardioversion. 2. pulmonary vein isolation for persistent atrial fibrillation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation

1\. electrical/pharmacological cardioversion. 2. pulmonary vein isolation for persistent atrial fibrillation

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with estabolished diagnosis of Persistent Atrial Fibrillation during past 6 mnths.
2. LAD brfore entering the two cohorts is more than 40mm, and less than 50mm.
3. Pharmacological or electrical cardioversion has be performed successfully.
4. At least two echocardiograms were performed before and 3-6 months after cardioversion., and confirm the status of LAD (Reversal, unchange, enlargment).
5. Patients have given informed consent.

Exclusion Criteria

1. Prior radiofrequency ablation treatment for atrial fibrillation
2. Prior cardiac surgical procedures
3. Individuals with cognitive impairments who are unable to give informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No